Novosti
Khirurgii
This journal is
indexed in Scopus



Year 2019 Vol. 27 No 1

REVIEWS

DOI: https://dx.doi.org/10.18484/2305-0047.2019.1.81   |  

E.M. SHARAFANOVICH 1, 2, N.E. KONOPLYA 1, V.I. AVERIN 3

CONTEMPORARY OPTIONS FOR MEDICAL TREATMENT OF PEDIATRIC VASCULAR LESIONS

Belarusian Medical Academy of Post-Graduate Education 1,
Republican Scientific and Practical Center for Pediatric Surgery 2,
Belarusian Medical State University 3, Minsk
The Republic of Belarus

Vascular lesions constitute a considerable part (about 25%) of pediatric benign tumors and tumor-like masses. According to up-to-date understanding of vascular lesions (anomalies) they are divided into two main groups: vascular tumors (characterized by growth through cell proliferation) and vascular malformations (structural abnormalities of vessels development).
The mechanism of action of drugs for vascular lesions systemic medication aims at proliferation and angiogenesis, therefore that kind of management has implement mostly to vascular tumors.
The most significant pediatric benign vascular tumor is infantile hemangioma (IH). The distinctive features of IH, as a separate nosology, are its typical clinical course with phases of proliferation and subsequent involution, GLUT1 expression at immune-histochemical staining, and also positive response to beta-blockers treatment, in particular, to non-selective beta-blocker propranolol that, at present, has got a main place in the management of this kind of vascular tumors.
In certain vascular malformations molecular-genetic researches of recent years have demonstrated alterations relating to cell cycle regulation and vasculature development. For clinical course improvement of some vascular malformations, a medical treatment can be also applied.
The article presents an up-to-date vascular lesions classification and terminology, describes options of medical management for vascular tumors and tumor-like masses, provides some of their pathogenetic aspects that determine the prospects of new pharmaco-therapeutic approaches to vascular anomalies management.

Keywords: hemangioma, vascular malformations, vascular neoplasms, infantile hemangioma, propranolol, beta blockers, targeted treatment
p. 81-90 of the original issue
References
  1. North PE, Waner M, Buckmiller L, James CA, Mihm MC Jr. Vascular tumors of infancy and childhood: beyond capillary hemangioma. Cardiovasc Pathol. 2006 Nov-Dec;15(6):303-17. doi: 10.1016/j.carpath.2006.03.001
  2. Mulliken JB, Glowacki J. Hemangiomas and Vascular Malformations in Infants and Children: A Classification Based on Endothelial Characteristics. Plast Reconstr Surg. 1982 Mar;69(3):412-22. https://www.uclahealth.org/head-neck-surgery/workfiles/Secure/HemangiomaClassification.pdf
  3. ISSVA Classification of vascular anomalies [Electronic resource]. International Society for the Study of Vascular Anomalies; 2014. [cited 2018 Jan 18]. Available from: http://issva.org/classification
  4. Dargeon HW, Adiao AC, Pack GT. Hemangioma with thrombocytopenia. J Pediatr. 1959 Mar;54(3):285-95. doi: 10.1016/S0022-3476(59)80002-0
  5. Edgerton MT. The treatment of hemangiomas with special reference to the role of steroid therapy. Ann Surg. 1976 May;183(5):517-32. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1344338/pdf/annsurg00279-0079.pdf
  6. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse Effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004 Aug;140(8):963-69. doi: 10.1001/archderm.140.8.963
  7. Kelly ME, Juern AM, Grossman WJ, Schauer DW, Drolet BA. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol. 2010 Jul;146(7):767-74. doi: 10.1001/archdermatol.2010.90
  8. Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc. 2004 Feb;79(2):243-45. doi: 10.4065/79.2.243
  9. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208-13. doi: 10.1001/archderm.137.9.1208
  10. Chantharatanapiboon W. Intralesional corticosteroid therapy in hemangiomas: clinical outcome in 160 cases. J Med Assoc Thai. 2008 Oct;91 (Suppl 3):S90-96. http://www.thaiscience.info/journals/Article/JMAT/10402472.pdf
  11. Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol. 2005 Feb;52(2):281-86. doi: 10.1016/j.jaad.2004.09.004
  12. Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg. 2010 Jun;29(2):106-14. doi: 10.1016/j.sder.2010.03.009
  13. Egbert JE, Schwartz GS, Walsh AW. Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. Am J Ophthalmol. 1996 Jun;121(6):638-42. doi: 10.1016/S0002-9394(14)70629-4
  14. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, Fahey JL, Derezin M, Weinstein WM, Casavante C, Rothman J, Rudnick SA, Voldberding PA. Recombinant Alpha-2 Interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1984 May;100(5):671-76. doi: 10.7326/0003-4819-100-5-671
  15. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987 Oct 1;47(19):5155-61. http://cancerres.aacrjournals.org/content/canres/47/19/5155.full.pdf
  16. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992 May 28;326(22):1456-63. doi: 10.1056/NEJM199205283262203
  17. Greinwald JH Jr, Burke DK, Bonthius DJ, Bauman NM, Smith RJ. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg. 1999 Jan;125(1):21-27. doi: 10.1001/archotol.125.1.21
  18. Dubois J, Hershon L, Carmant L, Bélanger S, Leclerc JM, David M. Toxicity profile of interferon alfa-2b in children: A prospective evaluation. J Pediatr. 1999 Dec;135(6):782-85. doi: 10.1016/S0022-3476(99)70104-6
  19. Michaud AP, Bauman NM, Burke DK, Manaligod JM, Smith RJ. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope. 2004 Jul;114(7):1231-36. doi: 10.1097/00005537-200407000-00017
  20. Kaselas C, Tsikopoulos G, Papouis G, Kaselas V. Intralesional administration of interferon A for the management of severe haemangiomas. Pediatr Surg Int. 2007 Mar;23(3):215-18. doi: 10.1007/s00383-006-1840-3
  21. Rush BF Jr. Treatment of a giant cutaneous hemangioma by intra-arterial injection of nitrogen mustard: case report. Ann Surg. 1966 Nov;164(5):921-23. https://journals.lww.com/annalsofsurgery/Citation/1966/11000/Treatment_of_a_Giant_Cutaneous_Hemangioma_by.22.aspx
  22. Hurvitz CH, Alkalay AL, Sloninsky L, Kallus M, Pomerance JJ. Cyclophosphamide therapy in life-threatening vascular tumors. J Pediatr. 1986 Aug;109(2):360-63. doi: 10.1016/S0022-3476(86)80405-X
  23. Enjolras O, Brevière GM, Roger G, Tovi M, Pellegrino B, Varotti E, Soupre V, Picard A, Leverger G. Vincristine treatment for function and life-threatening hemangiomas of infancy. Arch Pediatr. 2004 Feb;11(2):99-107. doi: 10.1016/j.arcped.2003.10.014
  24. Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg. 2004 Mar;57(2):168-71. doi: 10.1016/j.bjps.2003.11.003
  25. Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer. 2015 Apr;62(4):577-80. doi: 10.1002/pbc.25296
  26. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008 Jun 12;358(24):2649-51. doi: 10.1056/NEJMc0708819
  27. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L, MacLellan-Tobert S, Mancini AJ, Metry D, Puttgen KB, Seefeldt M, Sidbury R, Ward KM, Blei F, Baselga E, Cassidy L, Darrow DH, Joachim S, Kwon EK, Martin K, Perkins J, Siegel DH, Boucek RJ, Frieden IJ. Initiation and use of propranolol for infantile hemangioma: report of a Consensus Conference Pediatrics. Pediatrics. 2013 Jan;131(1):128-40. doi: 10.1542/peds.2012-1691
  28. Caussé S, Aubert H, Saint-Jean M, Puzenat E, Bursztejn AC, Eschard C, Mahé E, Maruani A, Mazereeuw-Hautier J, Dreyfus I, Miquel J, Chiaverini C, Boccara O, Hadj-Rabia S, Stalder JF, Barbarot S; Groupe de Recherche Clinique en Dermatologie Pédiatrique. Propranolol-resistant infantile haemangiomas. Br J Dermatol. 2013 Jul;169(1):125-29. doi: 10.1111/bjd.12417
  29. Lamy S, Lachambre MP, Lord-Dufour S, Beliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol. 2010 Nov-Dec;53(5-6):200-8. doi: 10.1016/j.vph.2010.08.002
  30. Tu JB, Ma RZ, Dong Q, Jiang F, Hu XY, Li QY, Pattar P, Zhang H. Induction of apoptosis in infantile hemangioma endothelial cells by propranolol. Exp Ther Med. 2013 Aug;6(2):574-78. doi: 10.3892/etm.2013.1159
  31. Bernabeu-Wittel J, Narváez-Moreno B, de la Torre-García JM, Fernández-Pineda I, Domínguez-Cruz JJ, Coserría-Sánchez F, Álvarez-del-Vayo C, Conejo-Mir J. Oral nadolol for children with infantile hemangiomas and sleep disturbances with oral propranolol. Pediatr Dermatol. 2015 Nov-Dec;32(6):853-57. doi: 10.1111/pde.12686
  32. Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol. 2015 Jan;172(1):13-23. doi: 10.1111/bjd.13379
  33. Ábarzúa-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol. 2014 Jun;70(6):1045-49. doi: 10.1016/j.jaad.2014.01.905
  34. Moehrle M, Leaute-Labreze C, Schmidt V, Rocken M, Poets CF, Goelz R. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol. 2013 Mar-Apr;30(2):245-49. doi: 10.1111/j.1525-1470.2012.01723.x
  35. Mashiah J, Kutz A, Rabia SH, Ilan EB, Goldberg I, Sprecher E, Harel A. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. Int J Dermatol. 2017 Feb;56(2):148-53. doi: 10.1111/ijd.13517
  36. Torres-Pradilla M, Baselga E. Failure of Intralesional Propranolol in Infantile Hemangiomas. Pediatr Dermatol. 2014 Mar-Apr;31(2):156-58. doi: 10.1111/pde.12175
  37. Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Engl J Med. 2012 Jan 26;366(4):384-86. doi: 10.1056/NEJMc1112482
  38. Rankin H, Zwicker K, Trenor CC. Caution is recommended prior to sildenafil use in vascular anomalies. Pediatr Blood Cancer. 2015 Nov;62(11):2015-17. doi: 10.1002/pbc.25600
  39. Horbach SE, Jolink F, van der Horst CM. Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes. Dermatol Ther. 2016 Nov;29(6):466-69. doi: 10.1111/dth.12398
  40. Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008 Jun;5(6):357-61. doi: 10.1038/ncponc1112
  41. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004 Apr;30(2):193-204. doi: 10.1016/j.ctrv.2003.07.007
  42. Perry B, Banyard J, McLaughlin ER, Watnick R, Sohn A, Brindley DN, Obata T, Cantley LC, Cohen C, Arbiser JL. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol. 2007 Apr;143(4):504-6. doi: 10.1001/archderm.143.4.504
  43. Shirazi F, Cohen C, Fried L, Arbiser JL. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol. 2007;5(4):233-36. doi: 10.1089/lrb.2007.1012
  44. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011 Dec 1;57(6):1018-24. doi: 10.1002/pbc.23124
  45. Strychowsky JE, Rahbar R, O’Hare MJ, Irace AL, Padua H, Trenor CC Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. Laryngoscope. 2018 Jan;128(1):269-76. doi: 10.1002/lary.26780
  46. Uno T, Ito S, Nakazawa A, Miyazaki O, Mori T, Terashima K. Successful treatment of Kaposiform hemangioendothelioma with everolimus. Pediatr Blood Cancer. 2015 Mar;62(3):536-38. doi: 10.1002/pbc.25241
  47. Uebelhoer M, Boon LM, Vikkula M. Vascular anomalies: from genetics toward models for therapeutic trials. Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a009688. doi: 10.1101/cshperspect.a009688
Address for correspondence:
220013, The Republic of Belarus,
Minsk, P. Brovko Str., 3-3,
Belarusian Medical Academy
Of Post-Graduate Education,
Department of Pediatric Oncology and Hematology.
Tel. mob.: +375 29 684-34-04,
e-mail: sharafanovich1@gmail.com,
Elena M. Sharafanovich
Information about the authors:
Sharafanovich Elena M., Applicant of the Department of Pediatric Oncology and Hematology, Belarusian Medical Academy of Post-Graduate Education, Pediatric Surgeon of the Surgical Unit №2, Republican Scientific and Practical Center for Pediatric Surgery, Minsk, Republic of Belarus.
https://orcid.org/0000-0003-4238-9926
Konoplya Natalya E., MD, Associate Professor, Professor of the Department of Pediatric Oncology and Hematology, Belarusian Medical Academy of Post-Graduate Education, Minsk, Republic of Belarus.
https://orcid.org/0000-0003-0592-7182
Averin Vasily I., MD, Professor, Head of the Department of Pediatric Surgery, Belarusian Medical State University, Minsk, Republic of Belarus.
https://orcid.org/0000-0003-3343-8810
Contacts | ©Vitebsk State Medical University, 2007